Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19 vaccines and have received emergency use authorization as therapeutics. However, viral escape mutants could compromise efficacy. To define immune-selected mutations in the S protein, we exposed a VSV-eGFP-SARS-Co...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhuoming, VanBlargan, Laura A., Bloyet, Louis-Marie, Rothlauf, Paul W., Chen, Rita E., Stumpf, Spencer, Zhao, Haiyan, Errico, John M., Theel, Elitza S., Liebeskind, Mariel J., Alford, Brynn, Buchser, William J., Ellebedy, Ali H., Fremont, Daved H., Diamond, Michael S., Whelan, Sean P.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839837/
https://www.ncbi.nlm.nih.gov/pubmed/33535027
http://dx.doi.org/10.1016/j.chom.2021.01.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839837/
https://www.ncbi.nlm.nih.gov/pubmed/33535027
http://dx.doi.org/10.1016/j.chom.2021.01.014

Ejemplares similares